<p><strong>在癌症生物学、RNA 生物学和转化治疗领域的公认专家，拥有 20 年的临床前肿瘤药物发现和开发经验</strong></p>
<p>佛罗里达州坦帕和伦敦，2026 年 2 月 26 日（全球新闻通讯）-- Akari Therapeutics, Plc（纳斯达克：AKTX），一家开发具有新型免疫肿瘤药物载荷的抗体药物偶联物（ADCs）的肿瘤生物技术公司，今天宣布任命 Prafulla Gokhale 博士，Dana-Farber 癌症研究所实验治疗核心和 Lurie 家庭成像中心主任，加入其科学顾问委员会。</p>
<p>“Gokhale 博士在实验治疗、RNA 生物学和转化肿瘤学方面的专业知识恰逢其时，因为我们正在推进 AKTX-101 进入临床阶段，” Akari Therapeutics 的总裁兼首席执行官 Abizer Gaslightwala 评论道。“他在开发新型转化实验/数据方面的成功记录，将加强我们的开发方法，帮助我们将 AKTX-101 推进到临床试验。随着我们逐步接近首次人体研究，他的见解将确保 AKTX-101 和我们新型的 PH1 剪接体调节载荷以集中、数据驱动的高影响力项目进入临床，以优化结果。”</p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/244fe78c-84c8-430c-b605-1cfd5de83a63/image1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/244fe78c-84c8-430c-b605-1cfd5de83a63/image1.png"/></p>
<p>Gokhale 博士在临床前肿瘤药物发现和开发方面拥有超过 20 年的经验。他的职业生涯始于乔治城大学放射医学系的教职，随后转向制药行业，在 OSI Pharmaceuticals、辉瑞和 Verastem 等公司担任逐步增加责任的_体内_药理学团队负责人。他目前担任 Dana-Farber 的实验治疗核心负责人，监督整合基因组学、分子生物学、患者衍生模型、成像和临床前研究的转化研究项目，以推进新型治疗策略。</p>
<p>Gokhale 博士表示：“我很高兴加入 Akari 的科学顾问委员会，并与一个推进真正差异化的 ADC 开发方法的团队合作。与依赖于微管抑制剂或 DNA 损伤剂的传统载荷策略不同，PH1 靶向 RNA 剪接，这是癌细胞生物学的基本调节因子。这一新机制有潜力破坏肿瘤生存通路，同时驱动独特的先天和适应性免疫系统参与。我期待与团队密切合作，进一步完善转化策略，并支持 AKTX-101 进入临床。”</p>
<p>Gokhale 博士的研究成果已广泛发表并获得资助，反映了他在将基础发现转化为癌症及相关疾病临床创新方面的领导力。</p>
<p><strong>关于 Akari Therapeutics</strong></p>
<p>Akari Therapeutics 是一家开发下一代抗体药物偶联物（ADCs）的肿瘤生物技术公司，其独特的载荷 PH1 靶向 RNA 剪接。利用其创新的 ADC 发现平台，公司能够生成 ADC 候选药物，并根据所需应用优化它们，以针对任何感兴趣的抗原靶点。Akari 的主要候选药物 AKTX-101 靶向癌细胞上的 Trop2 受体，并通过专有连接子使其能够将新型 PH1 载荷直接输送到肿瘤中，具有最小的脱靶效应。与当前使用微管抑制剂和 DNA 损伤剂作为载荷的 ADCs 不同，PH1 是一种新型载荷，是一种剪接体调节剂，旨在破坏癌细胞内的 RNA 剪接。这种剪接调节在临床前动物模型中已显示出诱导癌细胞死亡的能力，同时激活先天和适应性免疫系统，以驱动强大而持久的活性。在临床前研究中，AKTX-101 显示出相对于传统载荷的 ADCs 具有显著的活性和延长的生存期。此外，AKTX-101 与检查点抑制剂具有协同作用，并在单药和与检查点抑制剂联合使用时均显示出延长生存期。PH1 载荷在针对具有关键致癌驱动因子的癌细胞（如 KRAS、BRAF、ARV7、FGFR3 融合等）方面也表现出很强的活性。公司已启动 AKTX-101 的 IND 启用研究，目标是在 2026 年底/2027 年初开始首次人体试验。Akari 还在开发 AKTX-102，这是一种靶向 CEACAM5（癌胚抗原相关细胞粘附分子-5）的 ADC 候选药物，这是一种在多种实体肿瘤中广泛表达的经过良好验证的肿瘤抗原。AKTX-102 旨在利用 Akari 的专有 PH1 剪接体调节载荷和新型抗体结构，以实现差异化的肿瘤细胞杀伤和免疫激活。</p>
<p>有关公司的更多信息，请访问 www.akaritx.com，并在 X 和 LinkedIn 上与我们联系。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿包含根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的定义，关于公司的明确或隐含的前瞻性陈述，这些陈述涉及与未来事件和公司未来表现相关的风险和不确定性。实际事件或结果可能与这些前瞻性陈述有重大差异。诸如 “将”、“可能”、“会”、“应该”、“期望”、“计划”、“预期”、“打算”、“相信”、“估计”、“预测”、“项目”、“潜在”、“继续”、“未来”、“机会”、“可能导致”、“目标” 等词语及其变体，以及这些词的否定形式，旨在识别这些前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别词。这些前瞻性陈述的示例包括但不限于关于公司推进其癌症及其他疾病治疗产品候选药物的能力，以及最终将疗法带给患者的明确或隐含的陈述。这些陈述基于公司的当前计划、估计和预测。由于其本质，前瞻性陈述涉及固有的风险和不确定性，包括一般性和特定性。许多重要因素，包括本通讯中描述的因素，可能导致实际结果与任何前瞻性陈述中设想的结果有重大差异。可能影响未来结果并导致这些前瞻性陈述不准确的因素包括但不限于：公司对额外资本的需求；不可预见的负债、未来资本支出、收入、成本、费用、收益、协同效应、经济表现、债务、财务状况和损失对未来前景、业务和管理策略的潜在影响；与全球及地方政治和经济状况相关的风险，包括利率和汇率波动；与公司项目或产品候选药物的研究和/或开发相关的潜在延迟或失败；与公司专利或其他知识产权的任何损失相关的风险；原材料或公司产品候选药物制造的供应链中断，包括潜在关税导致的中断；公司及其合作伙伴或被许可方开发的产品候选药物的性质、时机、成本及可能的成功和治疗应用；公司及其合作伙伴或被许可方进行的研究和开发项目的结果在其他研究中复制的程度，以及是否能推动产品候选药物进入临床试验、治疗应用或获得监管批准；公司产品候选药物的利用、市场接受度和商业成功的不确定性；与公司产品候选药物的竞争相关的风险；以及公司成功开发或商业化其产品候选药物的能力。虽然上述因素的列表被认为是具有代表性的，但任何列表都不应被视为所有潜在风险和不确定性的完整陈述。有关公司及可能影响前瞻性陈述实现的风险因素的更详细信息已在公司向 SEC 提交的文件中列出，副本可从 SEC 网站 www.sec.gov 获取。公司不承担任何义务，并在此声明不更新本新闻稿中包含的前瞻性陈述，除非法律要求。</p>
<p><strong>投资者关系联系人</strong></p>
<p>JTC Team, LLC</p>
<p>Jenene Thomas</p>
<p>908-824-0775</p>
<p>AKTX@jtcir.com</p>
<p>与本公告相关的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/244fe78c-84c8-430c-b605-1cfd5de83a63 获取</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk1UZzFNQ00zTkRVMk5EQTRJekl3TWpBeU5qTT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk1UZzFNQ00zTkRVMk5EQTRJekl3TWpBeU5qTT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YmYwM2UzMmUtOGMzYi00NTliLTliNjQtN2Q0MGUyZjJkMGRkLTEwMzE4MzUtMjAyNi0wMi0yNi1lbg==/tiny/Akari-Therapeutics-Plc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YmYwM2UzMmUtOGMzYi00NTliLTliNjQtN2Q0MGUyZjJkMGRkLTEwMzE4MzUtMjAyNi0wMi0yNi1lbg==/tiny/Akari-Therapeutics-Plc.png"/></p>

Akari治疗

<p>Akari Therapeutics 已任命癌症和 RNA 生物学专家 Dr. Prafulla Gokhale 加入其科学顾问委员会。Gokhale 博士在肿瘤药物开发方面的丰富经验将支持 Akari 的主要候选药物 AKTX-101 的推进，该药物通过靶向 RNA 剪接来破坏癌细胞的生存。该公司计划在 2026 年底或 2027 年初启动 AKTX-101 的首个人体试验，重点是创新的治疗策略，以增强免疫系统对肿瘤的参与</p>

<p><strong>Recognized expert in cancer biology, RNA biology and translational therapeutics with 20 years of experience in preclinical oncology drug discovery and development</strong></p>
<div class="lb-trans"><p><strong>在癌症生物学、RNA 生物学和转化治疗领域的公认专家，拥有 20 年的临床前肿瘤药物发现和开发经验</strong></p>
</div><p>TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board.</p>
<div class="lb-trans"><p>佛罗里达州坦帕和伦敦，2026 年 2 月 26 日（全球新闻通讯）-- Akari Therapeutics, Plc（纳斯达克：AKTX），一家开发具有新型免疫肿瘤药物载荷的抗体药物偶联物（ADCs）的肿瘤生物技术公司，今天宣布任命 Prafulla Gokhale 博士，Dana-Farber 癌症研究所实验治疗核心和 Lurie 家庭成像中心主任，加入其科学顾问委员会。</p>
</div><p>“Dr. Gokhale’s expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic,” commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. “His proven track record to develop novel translational experiments/data that lead to well-designed and high-impact clinical strategies will strengthen our development approach as we advance AKTX-101 to clinical trials. As we move closer to first-in-human studies, his insight will help ensure that AKTX-101 and our novel PH1 spliceosome-modulating payload enter the clinic with a focused, data-driven high-impact program to optimize results.”</p>
<div class="lb-trans"><p>“Gokhale 博士在实验治疗、RNA 生物学和转化肿瘤学方面的专业知识恰逢其时，因为我们正在推进 AKTX-101 进入临床阶段，” Akari Therapeutics 的总裁兼首席执行官 Abizer Gaslightwala 评论道。“他在开发新型转化实验/数据方面的成功记录，将加强我们的开发方法，帮助我们将 AKTX-101 推进到临床试验。随着我们逐步接近首次人体研究，他的见解将确保 AKTX-101 和我们新型的 PH1 剪接体调节载荷以集中、数据驱动的高影响力项目进入临床，以优化结果。”</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/244fe78c-84c8-430c-b605-1cfd5de83a63/image1.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/244fe78c-84c8-430c-b605-1cfd5de83a63/image1.png"/></p>
<p>Dr. Gokhale has over 20 years of experience in preclinical oncology drug discovery and development. He began his career as a faculty member in the Radiation Medicine Department at Georgetown University before moving to the pharmaceutical industry, where he led <em>in vivo</em> pharmacology teams with increasing responsibility at OSI Pharmaceuticals, Pfizer, and Verastem. He currently heads the Experimental Therapeutics Core at Dana-Farber, overseeing translational research programs that integrate genomics, molecular biology, patient-derived models, imaging and preclinical studies to advance novel therapeutic strategies.</p>
<div class="lb-trans"><p>Gokhale 博士在临床前肿瘤药物发现和开发方面拥有超过 20 年的经验。他的职业生涯始于乔治城大学放射医学系的教职，随后转向制药行业，在 OSI Pharmaceuticals、辉瑞和 Verastem 等公司担任逐步增加责任的_体内_药理学团队负责人。他目前担任 Dana-Farber 的实验治疗核心负责人，监督整合基因组学、分子生物学、患者衍生模型、成像和临床前研究的转化研究项目，以推进新型治疗策略。</p>
</div><p>Dr. Gokhale commented, “I am excited to join Akari’s Scientific Advisory Board and work alongside a team advancing a truly differentiated approach to ADC development. Unlike conventional payload strategies that rely on tubulin inhibitors or DNA-damaging agents, PH1 targets RNA splicing, a fundamental regulator of cancer cell biology. This novel mechanism offers the potential to disrupt tumor survival pathways while also drive unique innate and adaptive immune system engagement. I look forward to collaborating closely with the team to further refine the translational strategy and support the advancement of AKTX-101 into the clinic.”</p>
<div class="lb-trans"><p>Gokhale 博士表示：“我很高兴加入 Akari 的科学顾问委员会，并与一个推进真正差异化的 ADC 开发方法的团队合作。与依赖于微管抑制剂或 DNA 损伤剂的传统载荷策略不同，PH1 靶向 RNA 剪接，这是癌细胞生物学的基本调节因子。这一新机制有潜力破坏肿瘤生存通路，同时驱动独特的先天和适应性免疫系统参与。我期待与团队密切合作，进一步完善转化策略，并支持 AKTX-101 进入临床。”</p>
</div><p>Dr. Gokhale’s work has been widely published and funded, reflecting his leadership in transforming fundamental discoveries into clinical innovations for cancer and related diseases.</p>
<div class="lb-trans"><p>Gokhale 博士的研究成果已广泛发表并获得资助，反映了他在将基础发现转化为癌症及相关疾病临床创新方面的领导力。</p>
</div><p><strong>About Akari Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Akari Therapeutics</strong></p>
</div><p>Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and novel antibody construct to enable differentiated tumor cell killing and immune activation.</p>
<div class="lb-trans"><p>Akari Therapeutics 是一家开发下一代抗体药物偶联物（ADCs）的肿瘤生物技术公司，其独特的载荷 PH1 靶向 RNA 剪接。利用其创新的 ADC 发现平台，公司能够生成 ADC 候选药物，并根据所需应用优化它们，以针对任何感兴趣的抗原靶点。Akari 的主要候选药物 AKTX-101 靶向癌细胞上的 Trop2 受体，并通过专有连接子使其能够将新型 PH1 载荷直接输送到肿瘤中，具有最小的脱靶效应。与当前使用微管抑制剂和 DNA 损伤剂作为载荷的 ADCs 不同，PH1 是一种新型载荷，是一种剪接体调节剂，旨在破坏癌细胞内的 RNA 剪接。这种剪接调节在临床前动物模型中已显示出诱导癌细胞死亡的能力，同时激活先天和适应性免疫系统，以驱动强大而持久的活性。在临床前研究中，AKTX-101 显示出相对于传统载荷的 ADCs 具有显著的活性和延长的生存期。此外，AKTX-101 与检查点抑制剂具有协同作用，并在单药和与检查点抑制剂联合使用时均显示出延长生存期。PH1 载荷在针对具有关键致癌驱动因子的癌细胞（如 KRAS、BRAF、ARV7、FGFR3 融合等）方面也表现出很强的活性。公司已启动 AKTX-101 的 IND 启用研究，目标是在 2026 年底/2027 年初开始首次人体试验。Akari 还在开发 AKTX-102，这是一种靶向 CEACAM5（癌胚抗原相关细胞粘附分子-5）的 ADC 候选药物，这是一种在多种实体肿瘤中广泛表达的经过良好验证的肿瘤抗原。AKTX-102 旨在利用 Akari 的专有 PH1 剪接体调节载荷和新型抗体结构，以实现差异化的肿瘤细胞杀伤和免疫激活。</p>
</div><p>For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.</p>
<div class="lb-trans"><p>有关公司的更多信息，请访问 www.akaritx.com，并在 X 和 LinkedIn 上与我们联系。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.</p>
<div class="lb-trans"><p>本新闻稿包含根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的定义，关于公司的明确或隐含的前瞻性陈述，这些陈述涉及与未来事件和公司未来表现相关的风险和不确定性。实际事件或结果可能与这些前瞻性陈述有重大差异。诸如 “将”、“可能”、“会”、“应该”、“期望”、“计划”、“预期”、“打算”、“相信”、“估计”、“预测”、“项目”、“潜在”、“继续”、“未来”、“机会”、“可能导致”、“目标” 等词语及其变体，以及这些词的否定形式，旨在识别这些前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别词。这些前瞻性陈述的示例包括但不限于关于公司推进其癌症及其他疾病治疗产品候选药物的能力，以及最终将疗法带给患者的明确或隐含的陈述。这些陈述基于公司的当前计划、估计和预测。由于其本质，前瞻性陈述涉及固有的风险和不确定性，包括一般性和特定性。许多重要因素，包括本通讯中描述的因素，可能导致实际结果与任何前瞻性陈述中设想的结果有重大差异。可能影响未来结果并导致这些前瞻性陈述不准确的因素包括但不限于：公司对额外资本的需求；不可预见的负债、未来资本支出、收入、成本、费用、收益、协同效应、经济表现、债务、财务状况和损失对未来前景、业务和管理策略的潜在影响；与全球及地方政治和经济状况相关的风险，包括利率和汇率波动；与公司项目或产品候选药物的研究和/或开发相关的潜在延迟或失败；与公司专利或其他知识产权的任何损失相关的风险；原材料或公司产品候选药物制造的供应链中断，包括潜在关税导致的中断；公司及其合作伙伴或被许可方开发的产品候选药物的性质、时机、成本及可能的成功和治疗应用；公司及其合作伙伴或被许可方进行的研究和开发项目的结果在其他研究中复制的程度，以及是否能推动产品候选药物进入临床试验、治疗应用或获得监管批准；公司产品候选药物的利用、市场接受度和商业成功的不确定性；与公司产品候选药物的竞争相关的风险；以及公司成功开发或商业化其产品候选药物的能力。虽然上述因素的列表被认为是具有代表性的，但任何列表都不应被视为所有潜在风险和不确定性的完整陈述。有关公司及可能影响前瞻性陈述实现的风险因素的更详细信息已在公司向 SEC 提交的文件中列出，副本可从 SEC 网站 www.sec.gov 获取。公司不承担任何义务，并在此声明不更新本新闻稿中包含的前瞻性陈述，除非法律要求。</p>
</div><p><strong>Investor Relations Contact</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系人</strong></p>
</div><p>JTC Team, LLC</p>
<div class="lb-trans"><p>JTC Team, LLC</p>
</div><p>Jenene Thomas</p>
<div class="lb-trans"><p>Jenene Thomas</p>
</div><p>908-824-0775</p>
<div class="lb-trans"><p>908-824-0775</p>
</div><p>AKTX@jtcir.com</p>
<div class="lb-trans"><p>AKTX@jtcir.com</p>
</div><p>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/244fe78c-84c8-430c-b605-1cfd5de83a63</p>
<div class="lb-trans"><p>与本公告相关的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/244fe78c-84c8-430c-b605-1cfd5de83a63 获取</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk1UZzFNQ00zTkRVMk5EQTRJekl3TWpBeU5qTT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY2MTg1MCM3NDU2NDA4IzIwMjAyNjM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YmYwM2UzMmUtOGMzYi00NTliLTliNjQtN2Q0MGUyZjJkMGRkLTEwMzE4MzUtMjAyNi0wMi0yNi1lbg==/tiny/Akari-Therapeutics-Plc.png" alt="" original-src="https://ml.globenewswire.com/media/YmYwM2UzMmUtOGMzYi00NTliLTliNjQtN2Q0MGUyZjJkMGRkLTEwMzE4MzUtMjAyNi0wMi0yNi1lbg==/tiny/Akari-Therapeutics-Plc.png"/></p>

Akari 治疗公司任命癌症生物学和 RNA 领域的顶尖专家 Prafulla Gokhale 博士加入科学顾问委员会 | AKTX 股票新闻